TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01815294
Drug: DOXIL/CAELYX (doxorubicin) Treatment Sequence BA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycle 1 = Treatment B, Cycle 2 = Treatment A
Study: NCT00070707
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo nasal spray, administered QD as 2 sprays in each nostril.
Study: NCT01018992
Drug: GSK561679
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK561679, oral administration, 350mg/day, 6 week administration
Study: NCT01018992
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo, oral administration, 1 pill/day for 6 weeks
Study: NCT04532333
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin should be administered each hour, 0.6mg/kg(75U/kg) as bolus dose, 0.3mg/kg 1h later, 10mg(1250U) every hour after.
Study: NCT01241448
Drug: LY2409021
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered Orally
Study: NCT01241448
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered Orally
Study: NCT02400749
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets will be provided to sites in blister cards.
Study: NCT03473665
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin Extended Release Oral Tablet 75mg every 12 hours for 6 weeks; omeprazole 20mg daily for 6 weeks
Study: NCT03473665
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac Delayed Release Oral Tablet 25mg tablets x 3 tablets every 12 hours for 6 weeks; omeprazole 20mg daily for 6 weeks
Study: NCT03473665
Drug: Meloxicam
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: meloxicam 7.5mg tablets every 12 hours for 6 weeks; omeprazole 20mg daily for 6 weeks
Study: NCT03473665
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib 200mg capsule every 12 hours for 6 weeks; omeprazole 20mg daily for 6 weeks
Study: NCT01185340
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01458288
Drug: TG-0054
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of four leukapheresis sessions)
Study: NCT00087516
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase A: Placebo matching Sitagliptin 100 mg once a day for 24 weeks. Phase B: Sitagliptin 100 mg once a day for 80 weeks.
Study: NCT00087516
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase A: Placebo matching Sitagliptin 200 mg once a day for 24 weeks. Phase B: Sitagliptin 200 mg once a day for 80 weeks.
Study: NCT00612521
Drug: Adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For lesions in the left coronary system the patient will receive either 120 micrograms of adenosine in 20 mls of normal saline or placebo prior to the wiring, pre-dilatation, stenting and post-dilatation of the target coronary stenosis. For lesions in the right coronary system the patient will receive either 60 micrograms of adenosine in 10 mls of normal saline or placebo prior to the wiring, pre-dilatation, stenting and post-dilatation of the target coronary stenosis.
Study: NCT02020200
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01581840
Drug: radiochemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy : PTV1 45 Gy 5 weeks PTV2 20 Gy 2 weeks Chemotherapy : 5Fu (400 to 1000 mg/m²) mitomycin : 10 mg/m²
Study: NCT03315936
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution
Study: NCT00329121
Drug: PEP005
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03491098
Drug: prednisolone sodium phosphate 15mg
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: three times per day for 1 week then gradual withdrawal over 2 weeks
Study: NCT00186498
Drug: Placebo Oral Capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received a placebo capsule starting the day before ECT begins and while receiving ECT
Study: NCT01147289
Drug: Dextralgen
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dexalgen® will be administered at a dose equivalent to dexamethasone 1.5 mg, dipyrone 500 mg, and hydroxocobalamin 5 mg (one ampoule for each type) a day at a single intramuscular dose. Both drugs will be administered for 3 days, at least.
Study: NCT01147289
Drug: Meloxicam
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meloxicam (Movatec®, Boehringer Ingelheim) will be administered as 15 mg (one ampoule) a day at a single intramuscular dose. Both drugs will be administered for 3 days, at least.
Study: NCT04371406
Drug: Hydroxychloroquine and Azithromycin
Normalized name: cefixime and azithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine sulfate (PLAQUENIL®), 200mg x 3 /d, for 10 days AND Azithromycin (ZITHROMAX®), 500mg on D1 and then 250mg/d for the next 4 days, in addition to standard of care
Study: NCT01039506
Drug: CPT-11 based regimens
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04257500
Drug: Etonogestrel/ethinyl estradiol vaginal ring
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 weeks of continuous use of contraceptive vaginal ring
Study: NCT02836158
Drug: R-IDARAM plus intrathecal chemotherapy
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-IDARAM comprised of rituximab 375 mg/m2 (day 1), idarubicin 10 mg/m2(day 2); dexamethasone 100 mg/m2 (12 h.infusion in day 2, 3 and 4); cytarabine 1 g/m2 (1 h. infusion in day 2); methotrexate 1.5 g/m2 (6 h. infusion in day 4 with folinic acid rescue). Intrathecal Immunochemotherapy comprised of rituximab 20mg, MTX 15mg, dexamethasone 5mg and Ara-c 50mg once a week.
Study: NCT00480896
Drug: Placebo ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application
Study: NCT00890175
Drug: Inhaled placebo @ 2 & 10 hours
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, 2 doses, 10 hours apart
Study: NCT02918500
Drug: Nicoderm Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine replacement therapy patch
Study: NCT00594191
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg/day p.o., increased to 40 mg/day at day 15 if no safety end-point was met
Study: NCT00594191
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with the same characteristics of the drug and at the same dose
Study: NCT00021034
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00113360
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose of 5 or 10 mg by mouth daily.
Study: NCT02238717
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching oral placebo
Study: NCT00792506
Drug: ITF2357
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment was to be administered on an inpatient basis from week 1 to week 13 and on an outpatient basis from week 14 to anticipated end of treatment (week 18). The patients had to be hospitalized on day 1 every week. The Investigator had to administer ITF 2357 in one single dose (two or three 200 mg capsules at one time) under his/her direct control.
Study: NCT00416442
Drug: RSV604
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01725386
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral tablet(s) administered according to prescribing information
Study: NCT00006232
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01216163
Drug: Novel Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single-dose of novel ibuprofen (equal to 400 mg ibuprofen)
Study: NCT01216163
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose of acetaminophen (1000mg)
Study: NCT01216163
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose of placebo
Study: NCT00152009
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04618263
Drug: GATE-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: GATE-101 is a metabotropic glutamate receptor type 2/3 antagonist
Study: NCT00993824
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02733705
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: fentanyl 0.5 mcg/kg ideal BW
Study: NCT01992705
Drug: -5-FU (Fluorouracil) 2,400 mg/m2 IV over 46-48 hours
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU (Fluorouracil) 2,400 mg/m2 IV over 46-48 hours of each cycle (21d/cycle for a total of 4 cycles.
Study: NCT04351243
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline
Study: NCT01156194
Drug: Homeopathy 1
Normalized name: Urtica urens homeopathic preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arnica montana C6 and Bellis perennis C6
Study: NCT01156194
Drug: Homeopathy 2
Normalized name: Urtica urens homeopathic preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arnica montana C30 and Bellis perennis C30
Study: NCT01156194
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: globule identical to true homeopathy comparators
Study: NCT00642837
Drug: Tramadol/acetaminophen
Normalized name: TRAMADOL/ACETAMINOPHEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteoarthritis, flexible dose depending on patients' pain relief
Study: NCT00642837
Drug: Tramadol/acetaminophen
Normalized name: TRAMADOL/ACETAMINOPHEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post surgical neurophatic pain, flexible dose depending on patients' pain relief
Study: NCT00642837
Drug: Tramadol/acetaminophen
Normalized name: TRAMADOL/ACETAMINOPHEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post traumatic neuropathic pain, flexible dose depending on patient pain relief
Study: NCT00642837
Drug: Tramadol/acetaminophen
Normalized name: TRAMADOL/ACETAMINOPHEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal Cord Injury, flexible dose depending on patients' pain relief
Study: NCT00642837
Drug: Tramadol/acetaminophen
Normalized name: TRAMADOL/ACETAMINOPHEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Failed Back Surgery Syndrome,flexible dose depending on patients' pain relief
Study: NCT00642837
Drug: Tramadol/acetaminophen
Normalized name: TRAMADOL/ACETAMINOPHEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetic Neuropathy, flexible dose depending on patients' pain relief
Study: NCT00642837
Drug: Tramadol/acetaminophen
Normalized name: TRAMADOL/ACETAMINOPHEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post stroke pain, flexible dose depending on patients' pain relief
Study: NCT00642837
Drug: Tramadol/acetaminophen
Normalized name: TRAMADOL/ACETAMINOPHEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low back pain, flexible dose depending on patients' pain relief
Study: NCT00642837
Drug: Tramadol/acetaminophen
Normalized name: TRAMADOL/ACETAMINOPHEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post Herpetic Neuralgia, flexible dose depending on patients' pain relief
Study: NCT00642837
Drug: Tramadol/acetaminophen
Normalized name: TRAMADOL/ACETAMINOPHEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex Regional Pain Syndrome, flexible dose depending on patients' pain relief
Study: NCT04146896
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered orally
Study: NCT00006115
Drug: FOLFIRI regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00006115
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00006115
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00006115
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02873819
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cyclophosphamide will be administered IV at a dose of 200 mg/m2 (maximum dose 400 mg) one day prior to first three vaccinations of GL0817 with adjuvants
Study: NCT02873819
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline) will be administered as per the schedule of cyclophosphamide and GL0817/adjuvants administration
Study: NCT00002658
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002658
Drug: tretinoin
Normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00009581
Drug: Acetylcholine
Normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00734253
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules taken twice a day for 1-year
Study: NCT02746042
Drug: Sinupret extract coated tablets
Normalized name: Plantago indica seed coat extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 coated tablet 3 times a day for 16-weeks (1-1-1)
Study: NCT02746042
Drug: Placebo coated tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 coated tablet 3 times a day for 16-weeks (1-1-1)
Study: NCT04191681
Drug: Usual care (standard-of-care) arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other oral vasodilator therapy to be continued or initiated to patients randomized to this arm, and titrated up every 2-4 weeks, per standard practice guidelines and label recommendations per physician's discretion.
Study: NCT02935673
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of matching placebo.
Study: NCT03681067
Drug: GSK1070806
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1070806 100mg/ml injectable solution will be delivered via intravenous infusion as a single infusion
Study: NCT01773707
Drug: CTLA4-Ig (Abatacept)
Normalized name: IG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given as 30 minute IV infusion
Study: NCT01773707
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline given as 30 minute IV infusion
Study: NCT01255709
Drug: Arm T1: Primatene Mist HFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: epinephrine inhalation aerosol, 90 mcg/inhalation, 12 inhalations over 6 minutes
Study: NCT01255709
Drug: Arm T2: Primatene Mist HFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: epinephrine inhalation aerosol, 100 mcg/inhalation, 12 inhalations over 6 minutes
Study: NCT01255709
Drug: Arm C: Primatene Mist (epinephrine inhalation aerosol, USP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: epinephrine inhalation aerosol, 220 mcg/inhalation, 12 inhalations over 6 minutes
Study: NCT01615354
Drug: Microgynon®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple oral doses
Study: NCT01615354
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple oral doses
Study: NCT01280734
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet or encapsulated tablet at 23:00
Study: NCT02468102
Drug: Standard of care drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: For DVT/PE treatment and SPAF, standard of care is treatment with the most widely used vitamin K antagonist, phenprocoumon, and for the secondary prevention of ACS, standard of care is antiplatelet drug(s) such as low-dose acetylsalicylic acid, clopidogrel, dipyridamole, prasugrel, ticlopidine and ticagrelor.
Study: NCT01268202
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pravastatin 40mg/day during 12 months
Study: NCT00911716
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02995850
Drug: CRS+HIPEC
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1. Ib~   * Dose-escalation of intraperitoneal paclitaxel will follow a modified 3 + 3 dose escalation procedure.~2. II~   ① CRS If PCI \<12, CRS will be performed by gastrectomy with D2-lymphadenectomy and resection of any involved adjacent structures.~   If PCI≥12, instead of CRS, 3 times of IP paclitaxel +cisplatin and oral S-1 chemotherapy every 3 weeks, and then PCI \<12, CRS will be done.~   ② Extensiveintraperitoneal lavage Peritoneal lavage after CRS will be done with 10 L before HIPEC.~   ③ HIPEC Following surgery HIPEC will be performed using CDDP (60 mg/m2) and PTX (P2RD mg/m2). IP chemotherapy will be performed.~   ④ Post-operative intraperitoneal chemotherapy Postoperative chemotherapy will be done 8 cycles of IP paclitaxel+ cisplatin and oral S-1 after 4 weeks.
Study: NCT00801528
Drug: Ropivacaine, Diclofenac, Water for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.2 %, or diclofenac (300 mg/240 ml water for injection) or water for injection will be administered as a constant instillation rate set of 10 mL/hr for the subsequent 18 postoperative hours.
Study: NCT00997152
Drug: JTT-654 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets
Study: NCT02391259
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: contains no active drug
Study: NCT02269072
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone cream applied daily for two weeks
Study: NCT02269072
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inert cream otherwise identical to testosterone cream applied daily for two weeks
Study: NCT00391651
Drug: TMP/SMX DS twice daily x 3 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMP/SMX DS twice daily x 3 days
Study: NCT04291456
Drug: Minocycline 100mg
Normalized name: minocycline 100 MG
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-arm trial of minocycline 100 mg twice daily
Study: NCT03026933
Drug: KI1107 4 Capsules, QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: KI1107 4 Capsules
Study: NCT03026933
Drug: Rosuvastatin Calcium 20 MG, QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin Calcium 20mg, QD
Study: NCT03204058
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prophylaxis followed by placement of placebo gel
Study: NCT03204058
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral prophylaxis followed by placement of rosuvastatin gel
Study: NCT01880359
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00817375
Drug: SSRI treated group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant administration of SSRI class for 6 weeks under therapeutic dose
Study: NCT00817375
Drug: non-SSRI treated group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant administration of non-SSRI class for 6 weeks under therapeutic dose
Study: NCT01370005
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching BI 10773 low dose
Study: NCT02933645
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects administer 2 intranasal sprays into each nostril every minute for 4 minutes, a total of 16 sprays. Sprays contain Insulin Diluting Medium for Novorapid and Levemir (Novo Nordisk A/S, Bagsvaerd, Denmark). The glass spray flasks are produced by AeroPump GmBH, Germany and give 0,1 ml of fluid per spray. To account for the small amount of insulin absorbed into circulation after the insulin nasal sprays, on the placebo day subjects will be administered 2.5 mU/kg of additional intravenous insulin (Actrapid, Novo Nordisk A/S, Bagsvaerd, Denmark) over 15 minutes.
Study: NCT04268498
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 650 mg administered PO.~Participants randomized to Arm C:~Cycles 1 through 8 - 650 mg administered on Days 1, 8 and 15.
Study: NCT01370005
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching BI 10773 high dose
Study: NCT01771822
Drug: Ibuprofen 5% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions
Study: NCT02294539
Drug: Losartan 50mg/Hydrochlorothiazide 12.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily, 1T, PO medication
Study: NCT00930631
Drug: [3H] BMS747158
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single bolus intravenous injection of \[3H\] BMS747158
Study: NCT01466517
Drug: Alivium®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400mg of Ibuprofen equivalent to 8mL (50mg/mL) oral suspension of the Reference Drug
Study: NCT01466517
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400mg of Ibuprofen equivalent to 10mL (40mg/mL) oral suspension of the Test Drug
Study: NCT02294539
Drug: Losartan 100mg/Hydrochlorothiazide 25mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily, 1T, PO medication
Study: NCT03581123
Drug: Standard Medical Care (SMC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline based medical care informed by the American College of Physicians' guidelines on noninvasive treatment for low back pain.
Study: NCT01202487
Drug: LET - Lidocaine Epinephrine Tetracaine
Normalized name: epinephrine / lidocaine / tetracaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: One time application of 3 cc of Lidocaine Epinephrine Tetracaine Solution at least 45 minutes prior to laceration repair
Study: NCT03672188
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
Study: NCT02161588
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily oral administration as tablets.
Study: NCT03701022
Drug: SHR1210
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1210 injection, 200 mg/dose, intravenous infusion within 20-60 minutes. Apatinib oral administration, 500mg per day.